Puma Biotechnology (PBYI) Other Accumulated Expenses (2011 - 2026)

Puma Biotechnology (PBYI) has 16 years of Other Accumulated Expenses data on file, last reported at $353000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses rose 20.07% year-over-year to $353000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $353000.0 (up 20.07% YoY) and the FY2025 annual result came in at $15.9 million, changed N/A from the prior year.
• Other Accumulated Expenses fell to $353000.0 in Q1 2026, from $15.9 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $16.5 million in Q4 2023 to a low of $81000.0 in Q3 2024.
• A 5-year average of $4.3 million and a median of $378500.0 in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses slumped 97.3% — and 2023, when it soared 7572.56%.
• Tracing PBYI's Other Accumulated Expenses over 5 years: stood at $215000.0 in 2022, then soared by 7572.56% to $16.5 million in 2023, then plunged by 99.51% to $81000.0 in 2024, then soared by 19477.78% to $15.9 million in 2025, then sank by 97.77% to $353000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $353000.0 (Q1 2026), $15.9 million (Q4 2025), and $171000.0 (Q3 2025), per Business Quant data.